Chair: Steven Kahn (USA) 17:45 – 17:50 Welcome and introduction Steven Kahn (USA) 17:50 – 18:05 Stepping up holistic care: incretin-based and novel combination therapies
17:45 – 17:53 Welcome and introduction TBC 17:53 – 18:08 The interplay of COVID-19 and cardiometabolic diseases TBC 18:08 – 18:23 The importance of staying
Chair: Michael Roden (DEU) 17:45 – 17:55 Introduction. The Growing Burden of MASLD/MASH: A Call to Action Michael Roden (DEU) 17:55 – 18:10 Need to
Chair: Alice Cheng (CAN) 17:45 – 17:50 Establishing a connection: addressing the relationship between cardio, renal and metabolic conditions Alice Cheng (CAN) 17:50 – 18:05
Chair: Ohad Cohen (CHE) Wednesday, 17 September 2025 16:00 – 16:30 CEST Arena
16:00 – 16:05 Why current pathways have become obsolete Lucien Engelen (NLD) 16:05 – 16:15 Co-creation of novel pathways via collaboration between primary and specialty
Coming soon… Tandem Diabetes Care, Inc. Wednesday, 17 September 2025 14:00 – 14:30 CEST Arena
Coming soon… Dexcom Wednesday, 17 September 2025 14:00 – 14:30 CEST Spotlight Stage
Chair: Paola Fioretto (ITA) 11:15 – 11:30 ‘”Hit Early Hit Hard”: Optimize treatment in people living with T2D and CKD Paola Fioretto (ITA) 11:30 –
Chair: Jonathan Rachman (GBR) 11:15 – 11:45 Disease modification in type 2 diabetes. What have we learnt? Stefano Del Prato (ITA)Jonathan Rachman (GBR) Eli Lilly
